查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生物仿製药市场规模、份额和趋势分析：按产品、按用途、按地区、按细分市场预测 2023-2030 年
市场调查报告书
商品编码
1321333

生物仿製药市场规模、份额和趋势分析：按产品、按用途、按地区、按细分市场预测 2023-2030 年

Biosimilars Market Size, Share & Trends Analysis By Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins), By Application (Rheumatoid Arthritis, Oncology), By Region And Segment Forecasts 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10个工作天内

价格

生物仿製药市场增长和趋势

Grand View Research, Inc.最新报告显示，预计2030年全球生物仿製药市场规模将达到762亿美元，2023年至2030年年复合成长率为15.9%。

该市场的增长是由患者和製造商的成本效益以及癌症和贫血等慢性非传染性疾病的患病率不断上升推动的。世界卫生组织 (WHO) 估计，40% 的 5 岁以下儿童和 30% 的 15 至 49 岁女性患有贫血。此外，生物仿製药提供几乎相似的结果，被认为是参考生物製剂更实惠的替代品。

由于它们几乎相似，生物製剂生产商也被迫降低价格以与生物仿製药竞争，从而降低总体治疗成本。例如，生物仿製药论坛于 2021 年 4 月发布的一份报告发现，生物仿製药的竞争加剧使生物製剂的价格平均下降了 56% 至高达 150%。此外，生物製剂拥有专利来防止生物仿製药的竞争。这些专利将生物仿製药的生产限制八到二十年，具体取决于国家法规。然而，许多挽救生命的生物製剂的专利预计将在预测期内到期，这可能会支持增长。

根据美国预算办公室 2021 年 4 月发表的报导，美国食品药品监督管理局 (FDA) 到 2020 年已批准了 29 种生物类似药，其中一些尚未推向市场。事实并非如此。此外，根据仿製药和生物仿製药计划中的报导，安进生物仿製药 Soliris 的上市时间已推迟到 2025 年。 COVID-19大流行的爆发对全球市场产生了不利影响。由于包括药品在内的各种产品的供应链受到干扰，并且大多数供应商都将重点放在了应对 COVID-19 的措施上，生物仿製药的生产面临着原材料短缺的问题。

例如，约翰·霍普金斯大学彭博公共卫生学院发布的一份报告发现，由于封锁，活性药物成分（API）供应出现短缺，而活性药物成分是用于製造药品的关键原材料。 。这些供应短缺直接影响了大流行期间生物仿製药和其他药物的生产和供应。然而，由于需求不断增加，多个市场参与者正在大力投资生物仿製药的研发，这可能会进一步推动市场增长。例如，提供先进生物技术解决方案的主要参与者安进公司已投资20亿美元开发10种生物仿製药。

生物仿製药市场报告亮点

  • 从产品来看，重组非糖基化蛋白细分市场在 2022 年的销售额中所占份额最大，为 54.9%。
  • 另一方面，由于多种挽救生命的生物製剂的专利预计即将到期，重组糖蛋白片段预计在预测期内将以 14.9% 的年复合成长率增长最快。
  • 由于慢性病和自身免疫性疾病的患病率不断上升，2022 年这些疾病的应用占据了最大的销售份额。
  • 由于癌症罹患率增加和重要生物製剂专利即将到期，预计肿瘤学在预测期内的年复合成长率为 17.0%。
  • 2022年，北美以40.4%的份额主导市场，有多个主要企业。与此同时，由于新产品的推出和医疗保健支出的增加，亚太地区预计将成为增长最快的地区，在预测期内年复合成长率为 18.4%。

目录

第1章调查方法和范围

  • 市场区隔和范围
  • 调查方法
  • 资讯采购
  • 资讯或资料分析
  • 市场形成和检验
  • 型号详情
  • 二手资讯清单
  • 主要资讯清单
  • 目的

第2章执行摘要

第3章生物仿製药市场变量、趋势和范围

  • 市场体系预测
    • 母公司市场预测
    • 相关/附市场预测
  • 采用和增长预测
  • 行业价值链分析
    • 赎回框架
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 生物类似药市场分析工具
    • 行业分析-搬运工
    • PESTEL分析

第4章生物仿製药市场：产品评估和趋势分析

  • 生物仿製药市场：关键要点
  • 生物仿製药市场：2022 年和 2030 年趋势和市场份额分析
  • 重组非糖基化蛋白
    • 2018-2030 年重组非糖基化蛋白市场估算和预测
    • 人类生长激素
    • 颗粒细胞增生因子
    • 干扰素
    • 胰岛素
  • 重组糖基化蛋白
    • 2018-2030年重组糖基化蛋白市场预测
    • 促红细胞生成素
    • 单克隆抗体
    • 促卵泡素

第5章生物仿製药市场：用途估算和趋势分析

  • 生物仿製药市场：关键要点
  • 生物仿製药市场：2022 年和 2030 年趋势和市场份额分析
  • 肿瘤学
  • 血液疾病
  • 生长激素缺乏症
  • 慢性和自身免疫性疾病
  • 其他的

第6章生物仿製药市场：区域估计和趋势分析

  • 区域预测
  • 按地区分類的生物仿製药市场：主要市场要点
  • 北美
    • 2018-2030 年市场估计和预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 鲷鱼
    • 韩国
  • 拉美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙特阿拉伯
    • 南非
    • 阿拉伯联合酋长国
    • 科威特

第7章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Amgen Inc.
    • F Hoffman La Roche Ltd.
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Samsung Biopis
    • Biocon
    • Viatris Inc.
    • Celltrion Healthcare Co., Ltd
    • AbbVie Inc.
Product Code: 978-1-68038-916-6

Biosimilars Market Growth & Trends

The global biosimilars market size is expected to reach USD 76.2 billion by 2030, registering a CAGR of 15.9% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of this market can be attributed to their cost effectiveness for both patients & manufacturers and the increasing prevalence of chronic & non-communicable diseases, such as cancer and anemia. According to the World Health Organizationestimates, 40% of children below five years of age, and 30% of women between the age group of 15 and 49 years are suffering from anemia. Moreover, biosimilar drugs offer almost similar results and are considered a more affordable alternative to their reference biologics.

Since they are almost similar, the producers of biologics also have to lower their prices to compete with biosimilars, which reduce the cost of the overall treatment. For instance, a report published by Biosimilars Forum in April 2021 suggests that increasing competition from biosimilars has resulted in lowering the prices of biologics by an average of 56% to up to 150%. Furthermore, biologics have patents to protect them from competing with biosimilars. These patents restrict the production of biosimilars for a period of 8 to 20 years depending on the regulations in different countries. However, patents of many lifesaving biologics are expected to expire during the forecast period, which can boost growth.

According to an article by Congressional Budget Office published in April 2021, the U.S. Food and Drugs Administration (FDA) had approved 29 biosimilar drugs by 2020, and some of them were yet to be introduced in the market. Furthermore, an article by Generics and Biosimilars Initiative suggests, the entry of Amgen's biosimilar Soliris was delayed till 2025. The outbreak of the COVID-19 pandemic had a negative impact on the global market. Since the supply chains of different products including pharmaceuticals were disrupted and most of the sources were dedicated to fighting COVID-19, the production of biosimilars experienced a shortage of raw materials.

For instance, according to a report published by Johns Hopkins Bloomberg School of Public Health, as a result of the lockdown, a shortage was observed in the supply of Active Pharmaceutical Ingredient (API), which is an important raw material used in producing drugs. These shortages directly affected the production and supply of biosimilars and other drugs during the pandemic. However, due to the increasing demand, several market players are significantly investing in the research & development of biosimilars, which can further add to the market growth. For instance, a key player offering advanced biotechnology solutions, Amgen Inc., has invested USD 2 billion in the development of 10 biosimilar medicines.

Biosimilars Market Report Highlights

  • Based on product, the recombinant non-glycosylated proteins segment accounted for the largest revenue share of 54.9% in 2022 due to a rise in the regulatory approvals for biosimilars from different governments
  • On the other hand, the recombinant glycosylated proteins segment is expected to grow at the fastest CAGR of 14.9% during the forecast period as the patents of several lifesaving biologics are expected to expire soon
  • The chronic and autoimmune disorders application segment accounted for the largest revenue share in 2022owing to the rising prevalence of these diseases
  • The oncology segment is expected to register the fastest CAGR of 17.0% during the forecast period due to the increasing prevalence of cancer and upcoming patent expiration for important biologics
  • In 2022, North America dominated the market with a share of 40.4% owing to the presence of several key players. On the other hand, Asia Pacific is anticipated to be the fastest-growing region at a CAGR of 18.4% over the forecast period due to new product launches and increasing healthcare expenditure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Application
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Biosimilars Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
    • 3.4.1. Market driver analysis
      • 3.4.1.1. Increasing emphasis on cutting down healthcare expenditure
      • 3.4.1.2. Cost-effectiveness of biosimilar drugs
      • 3.4.1.3. Positive outcome in the ongoing clinical trials
      • 3.4.1.4. R&D investments are increasing.
      • 3.4.1.5. Patent expiration of biologics to boost the biosimilars market
    • 3.4.2. Market restraint analysis
      • 3.4.2.1. High manufacturing complexities and costs
      • 3.4.2.2. Presence of non-original biologics and biobetters
  • 3.5. Biosimilars Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape

Chapter 4. Biosimilars Market: Product Estimates & Trend Analysis

  • 4.1. Biosimilars Market: Key Takeaways
  • 4.2. Biosimilars Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Recombinant Non-glycosylated Proteins
    • 4.3.1. Recombinant non-glycosylated proteins market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.2. Human growth hormone
      • 4.3.2.1. Human growth hormone market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.3. Granulocyte colony-stimulating factor
      • 4.3.3.1. Granulocyte colony-stimulating factor market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.4. Interferons
      • 4.3.4.1. Interferons market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.5. Insulin
      • 4.3.5.1. Insulin market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.4. Recombinant Glycosylated Proteins
    • 4.4.1. Recombinant glycosylated proteins market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.2. Erythropoietin
      • 4.4.2.1. Erythropoietin market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.3. Monoclonal antibodies
      • 4.4.3.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.4.4. Follitropin
      • 4.4.4.1. Follitropin market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 5. Biosimilars Market: Application Estimates & Trend Analysis

  • 5.1. Biosimilars Market: Key Takeaways
  • 5.2. Biosimilars Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Oncology
    • 5.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.4. Blood Disorders
    • 5.4.1. Blood disorders market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.5. Growth Hormonal Deficiency
    • 5.5.1. Growth hormonal deficiency market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.6. Chronic And Autoimmune Disorders
    • 5.6.1. Chronic and autoimmune disorders market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 6. Biosimilars Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Biosimilars Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Amgen Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. F Hoffman La Roche Ltd.
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Sandoz International GmbH
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Dr. Reddy's Laboratories Ltd.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Teva Pharmaceutical Industries Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Pfizer Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Samsung Biopis
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Biocon
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Viatris Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Celltrion Healthcare Co., Ltd
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. AbbVie Inc.
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 3 North America biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 4 North America biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 5 U.S. biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 6 U.S. biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 7 Canada biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 8 Canada biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 9 Europe biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 10 Europe biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 11 Europe biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 12 Germany biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 13 Germany biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 14 UK biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 15 UK biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 16 France biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 17 France biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 18 Italy biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 19 Italy biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 20 Spain biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 21 Spain biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 22 Sweden biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 23 Sweden biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 24 Norway biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 25 Norway biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 26 Denmark biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 27 Denmark biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 28 Asia Pacific biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 29 Asia Pacific biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 30 Asia Pacific biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 31 China biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 32 China biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 33 Japan biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 34 Japan biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 35 India biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 36 India biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 37 Thailand biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 38 Thailand biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 39 South Korea biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 40 South Korea biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 41 Latin America biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 42 Latin America biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 43 Latin America biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 44 Brazil biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 45 Brazil biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 46 Mexico biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 47 Mexico biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 48 Argentina biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 49 Argentina biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 50 Middle East and Africa biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 51 Middle East and Africa biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 52 Middle East and Africa biosimilars market, by region, 2018 - 2030 (USD Billion)
  • Table 53 South Africa biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 54 South Africa biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 55 Saudi Arabia biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 56 Saudi Arabia biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 57 UAE biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 58 UAE biosimilars market, by application, 2018 - 2030 (USD Billion)
  • Table 59 Kuwait biosimilars market, by product, 2018 - 2030 (USD Billion)
  • Table 60 Kuwait biosimilars market, by application, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Biosimilars market outlook
  • Fig. 9 Biosimilars competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Biosimilars market driver impact
  • Fig. 15 Biosimilars market restraint impact
  • Fig. 16 Biosimilars market strategic initiatives analysis
  • Fig. 17 Biosimilars market: Product movement analysis
  • Fig. 18 Biosimilars market: Product outlook and key takeaways
  • Fig. 19 Recombinant non-glycosylated proteins market estimates and forecasts, 2018 - 2030
  • Fig. 20 Recombinant glycosylated proteins market estimates and forecasts, 2018 - 2030
  • Fig. 21 Biosimilars market: Application movement analysis
  • Fig. 22 Biosimilars market: Application outlook and key takeaways
  • Fig. 23 Oncology market estimates and forecasts, 2018 - 2030
  • Fig. 24 Blood disorders market estimates and forecasts, 2018 - 2030
  • Fig. 25 Growth hormonal deficiency market estimates and forecasts, 2018 - 2030
  • Fig. 26 Rheumatoid arthritis market estimates and forecasts, 2018 - 2030
  • Fig. 27 Chronic and autoimmune disorders market estimates and forecasts, 2018 - 2030
  • Fig. 28 Others market estimates and forecasts, 2018 - 2030
  • Fig. 29 Global biosimilars market: Regional movement analysis
  • Fig. 30 Global biosimilars market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 34 Europe. market estimates and forecasts, 2018 - 2030
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 37 France market estimates and forecasts, 2018 - 2030
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 40 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 41 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 42 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 45 China market estimates and forecasts, 2018 - 2030
  • Fig. 46 India market estimates and forecasts, 2018 - 2030
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 54 Middle East and Africa. market estimates and forecasts, 2018 - 2030
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 56 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030